Patients with ovarian cancer have elevated 51Cr-EDTA plasma clearance early post-operatively

被引:1
|
作者
Nielsen, SS [1 ]
Havsteen, H [1 ]
Petersen, LK [1 ]
Nielsen, LE [1 ]
Rehling, M [1 ]
机构
[1] Aarhus Univ Hosp, Dept Clin Physiol & Nucl Med, Skejby Sygehus, DK-8200 Aarhus N, Denmark
关键词
Cr-51-EDTA plasma clearance; GFR; carboplatin treatment; ovarian cancer; surgery;
D O I
10.1097/00006231-200209000-00016
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Plasma clearance of Cr-51-EDTA (Clp(EDTA)) is widely used to determine glomerular filtration rate prior to carboplatin based chemotherapy. We have observed that many patients with ovarian cancer have elevated Clp(EDTA) in the early post-operative phase compared to later phases. The purpose of this study was to examine whether this observation reflects a systematic difference. We retrospectively analysed data from 53 patients who had undergone surgery for ovarian cancer. Twenty-six patients had Clp(EDTA) measured early after the operation (mean, 8 days (range, 3-16 days)) (early group), and 27 patients had Clp(EDTA) measured late post-operatively (mean, 32 days (range, 19-48 days)) (late group). Clp(EDTA) values was measured before the first, third and fifth course of chemotherapy. Additionally, age, height, weight, cancer stage, ascites and tumour histology were noted. Mean Clp(EDTA) in the early group was significantly higher than in the late group (104+/-4.4 vs 89 +/- 3.5 ml.min(-1) per 1.73 m(2); P = 0.005). Clp(EDTA) declined significantly in the early group from the first measurement after the operation until measurement before the third course of chemotherapy but remained constant in the late group. Clp(EDTA) was not correlated to ascites, cancer stage or tumour histology. It is concluded that patients with ovarian cancer have significantly higher Clp(EDTA) in the early post-operative phase than similar patients with Clp(EDTA) measured late postoperatively. ((C) 2002 Lippincott Williams Wilkins).
引用
收藏
页码:917 / 920
页数:4
相关论文
共 48 条
  • [1] Efficacy of 51Cr-EDTA clearance to calculate the dose of carboplatin in the treatment of ovarian cancer
    Dicembrino, F
    Varraso, A
    Martino, G
    Capotorto, AM
    Frusciante, V
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1999, 26 (09): : 1030 - 1030
  • [2] RENAL INULIN CLEARANCE VERSUS TOTAL PLASMA CLEARANCE OF 51CR-EDTA
    BROCHNER.J
    GIESE, J
    ROSSING, N
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1969, 23 (04): : 301 - &
  • [3] Total plasma clearance versus urinary plasma clearance of 51Cr-EDTA in patients with cirrhosis with and without fluid retention
    Henriksen, Ulrik L.
    Hansen, Hane B.
    Ring-Larsen, Helmer
    Bendtsen, Fleming
    Henriksen, Jens H.
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2015, 75 (01): : 64 - 72
  • [4] 51Cr-EDTA plasma clearance in children One, two, or multiple samples?
    Pottel, Hans
    Goffin, Karolien
    De Waele, Liesbeth
    Levtchenko, Elena
    Delanaye, Pierre
    MEDICINE, 2022, 101 (03)
  • [5] 51CR-EDTA PLASMA CLEARANCE IN CHILDREN: ONE, TWO OR MULTIPLE SAMPLES?
    Hans, Pottel
    Karolien, Goffin
    Liesbeth, De Waele
    Elena, Levtchenko
    Pierre, Delanaye
    PEDIATRIC NEPHROLOGY, 2021, 36 (10) : 3393 - 3394
  • [6] 51Cr-EDTA clearance estimation with single plasma sampling at 24 hr
    Pétursson, E
    Sigurdardóttir, S
    Jónsson, JJ
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1999, 26 (09): : 1118 - 1118
  • [7] Monitoring renal function in cancer patients treated with cytostatics. Is 51Cr-EDTA plasma clearance still needed?
    Hartley, L. B.
    Boeje, C. R.
    Palshof, T.
    Rehling, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S378 - S378
  • [8] Reliability of 51Cr-EDTA plasma and urinary clearance as a measure of residual renal function in dialysis patients
    Kjaergaard, Krista D.
    Jensen, Jens D.
    Jespersen, Bente
    Rehling, Michael
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2011, 71 (08): : 663 - 669
  • [9] Total plasma clearance of 51Cr-EDTA:: Variation with age and sex in normal adults
    Hamilton, D
    Riley, P
    Miola, U
    Mousa, D
    Popovich, W
    Al Khader, A
    NUCLEAR MEDICINE COMMUNICATIONS, 2000, 21 (02) : 187 - 192
  • [10] Efficacy of 51Cr-EDTA clearence to tailor a carboplatin therapeutic regimen in ovarian cancer patients
    Martino, G
    Frusciante, V
    Varraso, A
    Barbano, F
    Capotorto, A
    DiCembrino, F
    Petruzzelli, F
    Rubini, G
    ANTICANCER RESEARCH, 1999, 19 (6C) : 5587 - 5591